Alnylam Pharmaceuticals, Inc. (0HD2.L)
USD 243.84
(-0.72%)
USD 243.84
(-0.72%)
| Breakdown | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 |
|---|---|---|---|---|---|---|
| Operating Cash Flow | 104.15 Million | -541.27 Million | -641.69 Million | -614.96 Million | -278.42 Million | -562.61 Million |
| Net Income | -440.24 Million | -1.13 Billion | -852.82 Million | -858.28 Million | -886.11 Million | -761.49 Million |
| Depreciation & Amortization | 97.03 Million | 44.46 Million | 47.56 Million | 34.77 Million | 17.17 Million | 6.43 Million |
| Deferred income taxes | -399.36 Million | -150.91 Million | -37.5 Million | -48.21 Million | -118.19 Million | -150.34 Million |
| Stock-based compensation | 221.68 Million | 230.64 Million | 165.71 Million | 139.87 Million | 174.84 Million | 157.75 Million |
| Change in working capital | -125.1 Million | -35.55 Million | -162.82 Million | -12.7 Million | 402.38 Million | 45.09 Million |
| Other non-cash items | 350.79 Million | 749.63 Million | 549.73 Million | 382.45 Million | 279.13 Million | 152.14 Million |
| Investing Cash Flow | -336.35 Million | 169.35 Million | -273.3 Million | -435.51 Million | -417.67 Million | 272.94 Million |
| Investments in PPE | -62.21 Million | -72.05 Million | -76.37 Million | -70.36 Million | -140.15 Million | -126.88 Million |
| Acquisitions | - | -1.00 | - | -1.00 | - | - |
| Investment purchases | -1.88 Billion | -2.07 Billion | -1.69 Billion | -2.05 Billion | -2.07 Billion | -1.11 Billion |
| Sales/Maturities of investments | 1.61 Billion | 2.32 Billion | 1.5 Billion | 1.69 Billion | 1.8 Billion | 1.51 Billion |
| Other Investing Activities | -274.13 Million | -4.69 Million | -4.19 Million | -5.3 Million | -7 Million | 399.83 Million |
| Financing Cash Flow | 172.13 Million | 425.75 Million | 1.24 Billion | 994.97 Million | 823.18 Million | 65.47 Million |
| Debt repayment | - | -135.39 Million | -1 Billion | -686.59 Million | -30 Million | - |
| Dividends payments | - | - | - | - | - | - |
| Common Stock Repurchased | - | - | - | - | - | -3.46 Million |
| Common Stock Issuance | 147.46 Million | 259.36 Million | 246.26 Million | 299.98 Million | 853.18 Million | 68.93 Million |
| Other Financing Activities | 172.13 Million | 31 Million | 850 Thousand | 8.4 Million | 823.18 Million | 65.47 Million |
| Accounts receivables | -87.93 Million | -45.59 Million | -101.79 Million | -56.23 Million | -24.23 Million | 15.24 Million |
| Accounts payables | - | - | - | - | - | 15.47 Million |
| Inventory | 18.36 Million | -34.13 Million | -26.41 Million | -35.42 Million | -32.41 Million | -22.64 Million |
| Other working capital | -55.53 Million | 44.18 Million | -34.6 Million | 78.96 Million | 459.03 Million | 37.02 Million |
| Cash at beginning of period | 868.55 Million | 822.15 Million | 499.04 Million | 547.18 Million | 420.37 Million | 645.36 Million |
| Cash at end of period | 814.88 Million | 866.39 Million | 822.15 Million | 499.04 Million | 547.18 Million | 420.37 Million |
| Capital Expenditure | -62.21 Million | -72.05 Million | -76.37 Million | -70.36 Million | -140.15 Million | -126.88 Million |
| Effect of forex changes on cash | 6.39 Million | -7.43 Million | -9.01 Million | 4.91 Million | -83 Thousand | - |
| Net cash flow / Change in cash | -53.67 Million | 44.24 Million | 323.1 Million | -48.13 Million | 126.81 Million | -224.99 Million |
| Free Cash Flow | 41.94 Million | -613.33 Million | -718.06 Million | -685.32 Million | -418.58 Million | -689.5 Million |
| Breakdown | 2024 Q3 | 2024 Q2 | 2024 Q1 | 2023 FY | 2023 Q4 | 2023 Q3 |
|---|---|---|---|---|---|---|
| Operating Cash Flow | - | - | - | - | - | - |
| Net Income | -111.57 Million | -16.88 Million | -65.93 Million | -440.24 Million | -137.87 Million | 147.75 Million |
| Depreciation & Amortization | 13.98 Million | 24.69 Million | 13.51 Million | 54.05 Million | 13.48 Million | 13.32 Million |
| Deferred income taxes | - | - | - | -399.36 Million | -53.09 Million | 39.25 Million |
| Stock-based compensation | - | 89.28 Million | 45.34 Million | 221.68 Million | 41.99 Million | 63.93 Million |
| Change in working capital | 30.72 Million | 67.17 Million | -121.29 Million | 10.75 Million | 6.79 Million | 25.52 Million |
| Other non-cash items | 110.56 Million | -40.1 Million | 123.66 Million | 657.26 Million | 98.9 Million | 302.65 Million |
| Investing Cash Flow | -30.25 Million | 33.94 Million | -67.62 Million | -336.35 Million | -240.65 Million | -10.76 Million |
| Investments in PPE | -4.19 Million | -8.01 Million | -12.97 Million | -62.21 Million | -15.3 Million | -17.09 Million |
| Acquisitions | - | - | - | - | 225.34 Million | - |
| Investment purchases | -449.57 Million | -315.61 Million | -460.09 Million | -1.88 Billion | -589.15 Million | -421.45 Million |
| Sales/Maturities of investments | 423.51 Million | 357.56 Million | 405.44 Million | 1.61 Billion | 363.81 Million | 432.22 Million |
| Other Investing Activities | - | 41.95 Million | -54.64 Million | -4.43 Million | -225.34 Million | -4.43 Million |
| Financing Cash Flow | 102.75 Million | 131.49 Million | 28.91 Million | 172.13 Million | 39.22 Million | 33.13 Million |
| Debt repayment | - | - | - | - | - | - |
| Dividends payments | - | - | - | - | - | - |
| Common Stock Repurchased | - | - | - | - | - | - |
| Common Stock Issuance | 108.03 Million | 132.77 Million | 25.85 Million | 147.46 Million | 30.89 Million | 24.8 Million |
| Other Financing Activities | -5.28 Million | 131.49 Million | 3.05 Million | 24.66 Million | 8.33 Million | 8.33 Million |
| Accounts receivables | -37.09 Million | 9.64 Million | 410 Thousand | -87.93 Million | 3.86 Million | -107.99 Million |
| Accounts payables | 83.59 Million | 74.47 Million | -4.86 Million | - | -119.5 Million | 119.5 Million |
| Inventory | 5.92 Million | 6.79 Million | 22 Thousand | 18.36 Million | 11.99 Million | 4.79 Million |
| Other working capital | -21.69 Million | 50.73 Million | -116.86 Million | 80.33 Million | 110.43 Million | 9.21 Million |
| Cash at beginning of period | 968.49 Million | 684.71 Million | 812.68 Million | 866.39 Million | 1.03 Billion | 657.8 Million |
| Cash at end of period | 1.09 Billion | 971.19 Million | 681.87 Million | 812.68 Million | 812.68 Million | 1.03 Billion |
| Capital Expenditure | -4.19 Million | -8.01 Million | -12.97 Million | -62.21 Million | -15.3 Million | -17.09 Million |
| Effect of forex changes on cash | - | -3.12 Million | -9.94 Million | 6.39 Million | 10.89 Million | -6.55 Million |
| Net cash flow / Change in cash | 131.42 Million | 286.47 Million | -130.8 Million | -53.7 Million | -220.33 Million | 375.22 Million |
| Free Cash Flow | 39.51 Million | 116.14 Million | -94.48 Million | 41.94 Million | -45.1 Million | 342.32 Million |
688029
WILC
GUG
688283
VSMR
7944